These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38807655)

  • 1. LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced
    Lee ATM; Ou SI
    Lung Cancer (Auckl); 2024; 15():75-80. PubMed ID: 38807655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CNS Protective Effect of Selpercatinib in First-Line
    Pérol M; Solomon BJ; Goto K; Park K; Nadal E; Bria E; Martin C; Bar J; Williams JN; Puri T; Li J; Uh MK; Lin BK; Zhou C
    J Clin Oncol; 2024 Jul; 42(21):2500-2505. PubMed ID: 38828957
    [No Abstract]   [Full Text] [Related]  

  • 3. LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA
    Tsuboi M; Goldman JW; Wu YL; Johnson ML; Paz-Ares L; Yang JC; Besse B; Su W; Chao BH; Drilon A
    Future Oncol; 2022 Sep; 18(28):3133-3141. PubMed ID: 35950566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in
    Zhou C; Solomon B; Loong HH; Park K; Pérol M; Arriola E; Novello S; Han B; Zhou J; Ardizzoni A; Mak MP; Santini FC; Elamin YY; Drilon A; Wolf J; Payakachat N; Uh MK; Rajakumar D; Han H; Puri T; Soldatenkova V; Lin AB; Lin BK; Goto K;
    N Engl J Med; 2023 Nov; 389(20):1839-1850. PubMed ID: 37870973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.
    Subbiah V; Wolf J; Konda B; Kang H; Spira A; Weiss J; Takeda M; Ohe Y; Khan S; Ohashi K; Soldatenkova V; Szymczak S; Sullivan L; Wright J; Drilon A
    Lancet Oncol; 2022 Oct; 23(10):1261-1273. PubMed ID: 36108661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selpercatinib in Patients With
    Drilon A; Subbiah V; Gautschi O; Tomasini P; de Braud F; Solomon BJ; Shao-Weng Tan D; Alonso G; Wolf J; Park K; Goto K; Soldatenkova V; Szymczak S; Barker SS; Puri T; Bence Lin A; Loong H; Besse B
    J Clin Oncol; 2023 Jan; 41(2):385-394. PubMed ID: 36122315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world outcomes of chemoimmunotherapy and selective RET inhibitors in Chinese patients with RET fusion-positive non-small cell lung cancer.
    Wan R; Li W; Wang Z; Zhong J; Lin L; Duan J; Wang J
    Heliyon; 2024 Jan; 10(2):e24796. PubMed ID: 38304763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selpercatinib: A Review in Advanced RET Fusion-Positive NSCLC.
    Nie T; Syed YY
    Target Oncol; 2023 Jan; 18(1):169-176. PubMed ID: 36422787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Selpercatinib in
    Drilon A; Oxnard GR; Tan DSW; Loong HHF; Johnson M; Gainor J; McCoach CE; Gautschi O; Besse B; Cho BC; Peled N; Weiss J; Kim YJ; Ohe Y; Nishio M; Park K; Patel J; Seto T; Sakamoto T; Rosen E; Shah MH; Barlesi F; Cassier PA; Bazhenova L; De Braud F; Garralda E; Velcheti V; Satouchi M; Ohashi K; Pennell NA; Reckamp KL; Dy GK; Wolf J; Solomon B; Falchook G; Ebata K; Nguyen M; Nair B; Zhu EY; Yang L; Huang X; Olek E; Rothenberg SM; Goto K; Subbiah V
    N Engl J Med; 2020 Aug; 383(9):813-824. PubMed ID: 32846060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC).
    Nguyen VQ; Geirnaert M
    J Oncol Pharm Pract; 2023 Mar; 29(2):450-456. PubMed ID: 36572992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracranial Activity of Selpercatinib in Chinese Patients With Advanced
    Cheng Y; Huang D; Zhou J; Zhou C; Sun Y; Wu L; Guo Y; Jingxin S; Zhang W; Lu S
    JCO Precis Oncol; 2023 Jun; 7():e2200708. PubMed ID: 37315261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case report: First evidence of impressive efficacy of modulated dose selpercatinib in a young Caucasian with ANK3-RET fusion-positive NSCLC.
    De Carlo E; Bertoli E; Schiappacassi M; Stanzione B; Del Conte A; Doliana R; Spina M; Bearz A
    Front Oncol; 2024; 14():1307458. PubMed ID: 38420011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC Treated With Selpercatinib.
    Murciano-Goroff YR; Falcon CJ; Lin ST; Chacko C; Grimaldi G; Liu D; Wilhelm C; Iasonos A; Drilon A
    J Thorac Oncol; 2023 May; 18(5):620-627. PubMed ID: 36657661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of selpercatinib in Chinese patients with advanced
    Lu S; Cheng Y; Huang D; Sun Y; Wu L; Zhou C; Guo Y; Shao J; Zhang W; Zhou J
    Ther Adv Med Oncol; 2022; 14():17588359221105020. PubMed ID: 35923928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selpercatinib monotherapy in a Chinese patient with RET fusion/ EGFR co-mutated nonsmall cell lung cancer from the Phase II LIBRETTO-321 study: a case report.
    Wu L; Cheng Y; Huang D; Sun Y; Zhou C; Zhou J; Guo Y; Shao J; Zhang W; Lu S
    Anticancer Drugs; 2023 Oct; 34(9):1058-1064. PubMed ID: 37265026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced
    Lu S; Zheng X; Sun Y; Huang D; Wu L; Ji Q; Zhou C; Zhou J; Guo Y; Ge M; Ding D; Shao J; Zhang W; Gao M; Cheng Y
    Ther Adv Med Oncol; 2023; 15():17588359231189429. PubMed ID: 37655205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intracranial Efficacy of Selpercatinib in
    Subbiah V; Gainor JF; Oxnard GR; Tan DSW; Owen DH; Cho BC; Loong HH; McCoach CE; Weiss J; Kim YJ; Bazhenova L; Park K; Daga H; Besse B; Gautschi O; Rolfo C; Zhu EY; Kherani JF; Huang X; Kang S; Drilon A
    Clin Cancer Res; 2021 Aug; 27(15):4160-4167. PubMed ID: 34088726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program.
    Illini O; Hochmair MJ; Fabikan H; Weinlinger C; Tufman A; Swalduz A; Lamberg K; Hashemi SMS; Huemer F; Vikström A; Wermke M; Absenger G; Addeo A; Banerji S; Calles A; Clarke S; Di Maio M; Durand A; Duruisseaux M; Itchins M; Kääränien OS; Krenn F; Laack E; de Langen AJ; Mohorcic K; Pall G; Passaro A; Prager G; Rittmeyer A; Rothenstein J; Schumacher M; Wöll E; Valipour A
    Ther Adv Med Oncol; 2021; 13():17588359211019675. PubMed ID: 34178121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer.
    Rolfo C; Hess LM; Jen MH; Peterson P; Li X; Liu H; Lai Y; Sugihara T; Kiiskinen U; Vickers A; Summers Y
    ESMO Open; 2022 Aug; 7(4):100551. PubMed ID: 35930972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Additional Exclusions of
    Brazel D; Ou SI
    Lung Cancer (Auckl); 2023; 14():63-69. PubMed ID: 37383584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.